Euthymia in Bipolar Disorder: Meaning and Residual Symptoms
Ukrainian Psychological Hub · October 9, 2026 · Editorial Policy
Euthymia in bipolar disorder is a period of relatively stable mood in which a person is not experiencing a full manic, hypomanic, or major depressive episode. It is a clinically useful description of the present state. It does not establish that bipolar disorder has ended, that future episodes cannot occur, or that sleep, cognition, energy, and functioning have all returned to an individual's previous baseline. The National Institute of Mental Health describes bipolar disorder as an episodic condition with important periods between episodes, while the NICE bipolar disorder guideline addresses assessment and treatment during these intervals.
A person who is euthymic may feel well, maintain relationships, work, and pursue personal goals. Another may be free of a full mood episode while experiencing lingering fatigue, subtle depressive symptoms, disrupted sleep, difficulty concentrating, or anxiety. These concerns often appear under the terms residual, subthreshold, or subsyndromal symptoms. Their presence deserves clinical attention because the goal of long-term care includes quality of life and functioning as well as reduction of acute mood episodes. This guide examines what euthymia means, how it is assessed, why residual symptoms matter, what studies establish, and how clinicians support sustained stability.
For additional clinical context, see Bipolar Disorder: Symptoms, Types, Diagnosis, and Treatment and How Long Do Bipolar Episodes Last? Mania, Depression, and Recovery.
What does euthymia mean in bipolar disorder?
The term euthymia describes a comparatively balanced mood state. Everyday emotions remain possible and expected during euthymia: people can grieve, become excited, feel frustrated, or react to stress without entering a bipolar mood episode. A clinician considers the sustained pattern of symptoms, their departure from the person's usual state, duration, changes in energy and activity, and functional consequences. A short-lived emotional reaction is insufficient to establish mania, hypomania, or bipolar depression. For diagnostic background, see NIMH's clinical overview.
In research, euthymia is also an operational study category. Investigators may require low scores on mania and depression rating scales, no qualifying mood episode during a defined period, or a minimum interval of relative stability. The exact instruments, cutoffs, and observation periods vary. A participant accepted as euthymic in one study could exceed another study's permitted threshold of depressive symptoms. Reported prevalence of residual symptoms, cognitive difficulties, and sleep problems therefore depends partly on how the study selected participants. The systematic review of cognition in euthymic bipolar disorder is best understood through that methodological context.
The concept applies across bipolar I and bipolar II disorder and other relevant bipolar conditions. Bipolar I involves a history of at least one manic episode; bipolar II involves hypomanic and major depressive episodes without a lifetime manic episode. Both can include meaningful euthymic periods, residual symptoms, and functional challenges. The fact that someone looks or feels stable today cannot determine their lifetime bipolar subtype. A diagnosis requires careful examination of the longitudinal history.
Euthymia, remission, recovery, and functioning
For a broader discussion of long-term stability and outcomes, see Bipolar Disorder Recovery and Remission: Stability, Recurrence, and Outlook.
Euthymia, symptomatic remission, clinical recovery, functional recovery, and personal recovery address related but different outcomes. Euthymia describes current mood stability. Symptomatic remission means the relevant mood symptoms have fallen below a specified threshold. In some longitudinal studies, recovery requires sustained remission for a minimum time. Functional recovery evaluates whether the person can participate in activities that matter to them, including study, employment, social life, home responsibilities, and self-care. Personal recovery also concerns autonomy, quality of life, hope, and chosen goals.
Those outcomes may develop at different speeds. Someone can have few depressive or manic symptoms but continue recovering financially after impulsive decisions made during an episode. Another may be participating fully at work but have persistent insomnia or anxiety. The STEP-BD analysis by Marangell and colleagues examined functioning in participants with subsyndromal depressive symptoms, illustrating why an all-or-nothing account of recovery overlooks important lived outcomes. Clinical follow-up should measure both symptoms and daily functioning.
Euthymia is therefore best regarded as a valuable clinical state within an ongoing course, rather than the sole endpoint of care. A person can aim for fewer episodes, less residual symptom burden, safer treatment, improved sleep, stronger relationships, and better functioning at the same time. NICE's long-term care recommendations emphasize individualized recovery goals and consideration of work, education, and psychological needs.
Can someone be euthymic and still have bipolar symptoms?
Yes, depending on the clinical or research definition in use. Residual symptoms are difficulties remaining after an acute episode has substantially resolved. Subthreshold or subsyndromal symptoms fall below criteria for a complete mood episode, although the terms are used with varying precision across studies. For example, a person may report diminished interest, mildly depressed mood, insomnia, low energy, or difficulty concentrating without meeting the duration and symptom-count requirements for major depression.
Longitudinal research shows why lower-level symptoms matter. In a prospective study of bipolar I disorder, Judd and colleagues followed weekly symptomatic status and identified substantial time with symptoms below the threshold for a full episode, especially depressive symptoms. This finding describes patterns in the investigated cohort; it is not a prediction that every person with bipolar disorder will experience the same course.
Some stricter investigators use euthymia only when mood symptoms are minimal; others permit limited remaining symptoms. These differences should be stated whenever a research finding is applied. A clinician hearing that someone is euthymic should still ask which symptoms have actually subsided, what difficulties remain, and how life has changed since the most recent episode.
Residual depression: low mood, motivation, and fatigue
Residual depressive symptoms can include low or flattened mood, a reduced ability to enjoy activities, hopelessness, guilt, diminished motivation, social withdrawal, changes in sleep or appetite, low energy, and difficulty completing ordinary tasks. The number, persistence, and severity of these symptoms determine whether they remain subthreshold or warrant reassessment for a full depressive episode. Even when criteria for major depression are not met, persistent symptoms can be distressing and interfere with work and relationships.
In the STEP-BD research program, Marangell et al. compared people classified as recovered, those with subsyndromal depressive symptoms, and those still experiencing major depression. Subsyndromal symptoms were associated with significant functional difficulties. This relationship does not demonstrate that every functional problem is directly caused by a particular symptom; sleep, medication effects, coexisting illnesses, and circumstances also contribute.
If a person describes being emotionally flat or exhausted, useful clinical questions include whether the problem began with the last episode, worsens after poor sleep, appeared following a medication adjustment, or is present alongside loss of interest and self-critical thinking. Physical contributors such as thyroid disease, anemia, pain, and sleep disorders may need assessment. Low motivation should not automatically be interpreted as a failure of effort or an enduring personality characteristic.
Residual activation, irritability, and mixed presentations
Mood stability also requires attention to increased activation. Emerging racing thoughts, unusually high activity, impulsive spending, pronounced talkativeness, rising confidence, agitation, and a marked decrease in the need for sleep may be warning signs when they form a sustained change from baseline. Hypomania and mania require a characteristic clinical syndrome; a brief period of enthusiasm or irritability alone cannot establish either diagnosis. NIMH explains the episode patterns and their consequences.
Irritability is especially nonspecific. It can accompany sleep deprivation, anxiety, interpersonal stress, some medication adverse effects, depressive episodes, or emerging mania. Restlessness can also arise from medication-induced akathisia. Assessing timing, sleep, energy, impairment, and additional symptoms helps determine what an observation means.
Depressive symptoms and activation can coexist in presentations involving mixed features. A combination of severe agitation, reduced sleep, despair, or impulsivity deserves timely assessment, including direct evaluation of safety. The management of acute mania and mixed presentations differs from care during euthymia. The 2023 VA/DoD guideline describes phase-specific assessment and treatment, while NICE addresses urgent referral when mania or severe depression is suspected.
Sleep and circadian rhythms during euthymia
For a dedicated exploration of sleep and episode prevention, see Bipolar Disorder and Sleep: Mood Episodes, Circadian Rhythms, and Prevention.
Sleep can be problematic even when a person's mood appears stable. Difficulties may involve delayed sleep onset, waking repeatedly, irregular bedtime, excessive time in bed, nonrestorative sleep, or daytime sleepiness. These symptoms can result from many factors, including anxiety, shift work, medications, pain, sleep apnea, and changes in daily structure. Clinical interpretation should investigate the full context.
A 2025 systematic review and meta-analysis of sleep across bipolar mood phases synthesized 44 studies. The authors reported substantial sleep difficulties in euthymic samples; approximately half of euthymic participants in relevant prevalence studies reported poor sleep quality. Estimates varied across populations and assessment methods. Subjective accounts and objective measures were not always aligned, so the pooled estimate does not give an individual diagnosis or probability.
Regular sleep and waking schedules can provide a useful foundation for long-term management. A change from needing seven or eight hours of sleep to sleeping only a few hours without feeling tired, especially alongside greater energy and risk taking, warrants attention as a possible early warning sign. Increased sleep with low mood and loss of interest can also signal a change, while remaining compatible with non-bipolar explanations. The NICE relapse-planning recommendations advise identifying individual warning signs and triggers.
Sleep difficulties often call for an individualized plan rather than rigid behavioral rules. A clinician may review work timing, nighttime stimulation, breathing-related sleep problems, substances, medical conditions, and medication effects. A sleep record is useful when it supports decisions without turning ordinary variations into a source of anxiety.
Thinking, memory, attention, and concentration
Some people notice persistent problems with verbal memory, processing speed, attention, executive functions, planning, or working memory between mood episodes. These concerns can affect reading, organizing appointments, completing multistep projects, and keeping up at work. However, cognitive complaints are not specific to bipolar disorder, and they cannot establish whether someone is euthymic or diagnose a bipolar condition.
A 2025 systematic review and meta-analysis combined 75 studies involving 4,404 participants with euthymic bipolar disorder and 4,037 controls. Group-level differences were observed across domains including verbal learning and memory, working memory, processing speed, executive functioning, and attention. The studies also exhibited heterogeneity, meaning individual outcomes can differ greatly from the overall average. These group findings do not imply that all people with bipolar disorder have persistent cognitive impairment.
Clinical assessment may review whether concentration was difficult before the first mood episode, whether it fluctuates with sleep and mood, and whether medications or medical conditions contribute. ADHD, anxiety, depression, substance use, and neurological or sleep problems may also affect cognition. When difficulties substantially limit function, a clinician may consider structured cognitive assessment and practical support.
Useful accommodations can include written reminders, adjusted schedules, manageable task sequencing, quiet work environments, and realistic pacing. These are pragmatic strategies to address observed problems rather than a promise that any intervention will reverse a specific biological deficit. Decisions about rehabilitation and further investigation are guided by the person's circumstances and evidence for the proposed approach.
Quality of life and functioning between episodes
A good outcome includes much more than a low score on a mood scale. People may want to sustain employment, care for children, study reliably, resume exercise, spend time with friends, rebuild confidence, or simply enjoy daily life without constant fear of recurrence. Each goal may involve physical health, finances, relationships, stigma, access to services, and the aftermath of previous episodes.
In a 2026 systematic review and meta-analysis of 27 comparative studies, investigators assessed quality-of-life outcomes among 2,055 euthymic patients and 3,576 controls. They identified group-level differences across several quality-of-life domains, including physical well-being and social relationships. Because the included studies used different populations, instruments, and largely observational comparisons, their results cannot identify one cause for every person's difficulties.
Functional recovery may also lag behind improvement in mood. Someone returning to work after a major depressive episode may need time to restore energy and confidence, while another recovering from mania may need support with financial or relationship consequences. A collaborative plan sets concrete, achievable goals and reviews progress. The NICE guideline recognizes occupational, educational, and broader psychosocial support as elements of management.
Does euthymia guarantee that bipolar disorder will remain stable?
For individualized relapse patterns and timely recognition of change, see Early Warning Signs of Mania and Bipolar Relapse.
Euthymia describes how the person is doing now. It does not establish how the next months or years will unfold. Many people enjoy prolonged stability, while others experience recurrent episodes. Individual course depends on previous episodes, treatment history and response, sleep patterns, comorbidity, substance use, psychosocial stressors, and other factors. No single observation predicts the timing of the next episode with certainty.
The STEP-BD analysis by Perlis and colleagues studied predictors of recurrence after recovery and supports the importance of longitudinal follow-up. Associations between a symptom and subsequent course do not automatically demonstrate causation. Residual symptoms can signal the need to reconsider care without implying that another episode is inevitable.
Progress is often most meaningful across months: whether stability is sustained, major episodes become less frequent, residual depression diminishes, sleep improves, daily activity becomes easier, and treatment remains tolerable. The CANMAT/ISBD 2023 update situates maintenance care within prevention of recurrence and restoration of well-being and functioning.
How do clinicians assess euthymia?
Assessment begins with the lifetime history of mood episodes, including the onset and duration of mania, hypomania, bipolar depression, mixed or psychotic features, treatment responses, and functional consequences. During follow-up, a clinician examines current mood, energy, activity, sleep, concentration, relationships, occupational function, medication adherence and tolerability, substance use, and any safety concerns. With the person's agreement, observations from a close supporter may add useful context. NICE emphasizes a thorough history and functional assessment.
Rating scales can support symptom measurement and longitudinal monitoring, but the threshold for research-defined euthymia is not a universal diagnostic standard. Mania and depression scales, structured interviews, patient-reported sleep records, and function measures answer different questions. A low score on one scale may coexist with significant difficulty in another domain. Scales therefore supplement, rather than replace, a clinical evaluation.
A useful review asks when symptoms began, what changed after an episode, which problems interfere with ordinary life, and whether the changes are associated with sleep, medical illness, stress, or medication. Anxiety, persistent attention difficulties, sleep apnea, thyroid disorders, substance use, and adverse drug effects can produce overlapping complaints. The VA/DoD guidance and NICE recommendations support attention to co-occurring conditions and treatment safety.
What might a person tell their care team?
Specific observations can make appointments more productive: 'My mood is steady, but I am exhausted after lunch'; 'I enjoy things again, but cannot concentrate at work'; 'I have slept three hours each night and do not feel tired'; or 'The restlessness started after my dose was increased.' Timing and change from baseline are often more informative than assigning a diagnostic label to oneself. Questions about medication side effects and personal treatment goals belong in the same conversation.
The clinician and patient can agree on measures that matter to the person, such as reliable sleep, fewer days of sadness, improved social engagement, safer spending, or the ability to carry out specific responsibilities. Follow-up can then evaluate whether an intervention is delivering those outcomes alongside protection from new episodes.
Why can residual symptoms persist?
There is no single established explanation for every symptom experienced between episodes. Bipolar disorders are heterogeneous, and several contributors may overlap: remaining depressive symptoms, circadian disruption, physical illness, anxiety, substance use, medication effects, social stress, cognitive difficulties, and consequences of earlier episodes. Individual differences in history and treatment also matter. Research continues to investigate biological and psychosocial mechanisms, and there is no single routine biomarker that determines whether someone is euthymic.
Interpretation of research requires care. A group-level difference in memory or sleep does not mean irreversible damage has occurred in an individual. A correlation between residual depressive symptoms and functional impairment does not isolate one cause. The heterogeneous findings in Swidzinski and colleagues' cognitive review and Marchetti and colleagues' sleep review illustrate why measurement and alternative explanations are central.
Treatment and ongoing care during euthymia
The main objectives of interepisode care are maintaining stability, preventing recurrence, reducing meaningful residual symptoms, managing adverse effects, supporting physical health, and improving the person's chosen areas of functioning. Plans depend on bipolar subtype, previous episode polarity and severity, history of response, other conditions, reproductive circumstances, safety considerations, and personal preferences. The 2023 CANMAT/ISBD update, 2023 VA/DoD guideline, and NICE CG185 offer complementary frameworks.
Maintenance medication is phase-specific
For a treatment-phase overview, see Bipolar Maintenance Treatment: Preventing Relapse Over Time.
Long-term pharmacological treatment is often important even after mood symptoms improve. Lithium has a substantial maintenance evidence base and may be particularly useful for some patients, but requires blood-level monitoring and surveillance of kidney and thyroid function. Certain atypical antipsychotics and anticonvulsant agents can be appropriate in selected circumstances. A medication used for acute mania should not automatically be assumed to be effective for bipolar depression or for prevention of every type of episode; the evidence depends on the drug, diagnosis, treatment phase, and outcome.
Safety remains important during apparent stability. Lithium levels can change with dehydration, physical illness, or interactions including nonsteroidal anti-inflammatory drugs, and toxicity requires urgent clinical assessment. Lamotrigine requires monitoring for serious rash, especially during titration or after interrupted treatment; valproate carries major reproductive and other risks; antipsychotics may cause metabolic and movement-related adverse effects. Medication-related fatigue, weight changes, tremor, or cognitive slowing may warrant review. NICE medication recommendations and CANMAT/ISBD guidance describe monitoring, risk assessment, and phase-specific choices.
Antidepressants require special consideration in bipolar disorder because benefits, risks, and potential mood switching depend on bipolar subtype, current phase, co-treatment, and individual history. Antidepressant monotherapy is generally inappropriate for bipolar I depression, and long-term use should be reviewed case by case. Pregnancy or plans to become pregnant require individualized specialist discussion because some medicines have serious reproductive risks. Stable mood should prompt a thoughtful review of benefits and burdens, not independent dose reduction or abrupt discontinuation.
Psychological care and functional support
Structured bipolar-specific psychoeducation can help people identify episode patterns and warning signs, recognize the purpose of maintenance treatment, plan for stress, and develop strategies for sleep and daily rhythms. Cognitive behavioral, family-focused, and other structured psychological interventions may also contribute, with evidence and indications depending on the phase of illness and treatment goal. NICE guidance on psychological interventions recommends appropriate structured approaches to help prevent relapse and to address symptoms that persist between major mood episodes.
Psychological treatment may also address fear of recurrence, low confidence, relationship strain, stigma, and the consequences of previous episodes. Co-occurring sleep disorders, anxiety, trauma-related difficulties, and substance use should be evaluated with their own evidence bases. The person's goals, preferences, and available support shape the plan.
A practical approach to life between episodes
Regular follow-up can remain useful through long periods of stability. The person and their care team can periodically review mood, sleep, medication benefits and adverse effects, physical health monitoring, work or study, family functioning, and goals. A plan for relapse prevention is most effective when it reflects the person's actual earlier episodes and the warning signs they can recognize. NICE recommends documenting triggers, warning signs, preferred responses, and services to contact.
A short record can track sleep duration, unusual decreases in the need for sleep, energy, mood, concentration, and participation in important tasks. It should be proportionate and useful rather than an obligation to monitor every emotion. Some people benefit from discussing the plan with a partner or family member who understands which sustained changes warrant concern and how to communicate respectfully.
A shared plan may identify practical next steps: contact a clinician after several nights of rapidly reduced sleep, seek reassessment when depressive symptoms steadily worsen, review medication side effects rather than changing doses alone, and use agreed crisis contacts when functioning or safety deteriorates. The best plan respects autonomy and supports early intervention.
When to seek urgent help
Urgent professional assessment is appropriate when severe or rapidly escalating mania, psychosis, dangerous impulsivity, markedly impaired judgment, inability to meet basic needs, or severe depression with suicidal thinking is suspected. A pattern of very little sleep combined with rapidly increasing energy, grandiosity, and risky behavior requires attention even before all episode criteria are confirmed. NICE referral guidance addresses urgent evaluation for suspected mania, severe depression, and threats to safety.
When there is immediate danger, contact local emergency services or go to an emergency department. In the United States, call or text 988 for the Suicide & Crisis Lifeline; call 911 for a life-threatening emergency. A person who cannot stay safe or is experiencing new suicidal or psychotic symptoms should receive prompt assessment regardless of whether they were recently described as euthymic. NIMH provides U.S. crisis resources.
What research establishes—and what remains uncertain
Prospective studies establish that symptoms below full episode thresholds can be clinically important. The cohorts studied by Judd et al. and Perlis et al. clarify aspects of long-term course and recurrence, while Marangell et al. documents relationships between subsyndromal depression and daily functioning. Their populations and outcome definitions differ, so results should not be combined into one universal prediction.
Systematic reviews support group-level observations of persistent cognitive differences, sleep problems, and lower quality-of-life scores in some euthymic samples. Swidzinski et al., Marchetti et al., and Wang et al. investigate different outcomes and include varied methods and clinical samples. These estimates are descriptive, do not diagnose individuals, and cannot establish that the group-level difference has one common cause.
Evidence for exactly how to treat every form of residual symptom remains less settled. Clinical trials of interventions for particular mood phases cannot automatically be generalized to all interepisode complaints or all patient groups. Phase-specific recommendations, individualized assessment, and careful follow-up therefore remain essential. VA/DoD and CANMAT/ISBD distinguish phases and treatment purposes.
Common misconceptions
Euthymia is sometimes misunderstood as constant happiness. In clinical use, it means comparatively stable mood, including the ordinary range of human emotional reactions. Another misconception is that an absence of a major mood episode means no further care is valuable. Long-term treatment and monitoring can remain appropriate, and interepisode functioning deserves direct attention. NIMH and NICE describe ongoing management as part of bipolar care.
A third misconception is that any remaining fatigue, irritability, or difficulty concentrating proves an active bipolar episode. Such symptoms may have multiple explanations, including sleep, medication adverse effects, physical illness, and co-occurring conditions. Clinical assessment seeks the relevant pattern, severity, timing, and effect on function.
Frequently asked questions
Is euthymia a cure for bipolar disorder?
Euthymia is a stable mood state, not a statement that the lifetime diagnosis has disappeared. A person may remain well for an extended period while still benefiting from a relapse-prevention plan, medical monitoring, and follow-up based on their history. NIMH emphasizes continuing care.
How long does euthymia last?
It varies considerably among individuals. Some have brief intervals of relative stability; others remain stable for years. Studies may require a minimum symptom-free period to classify a sample as euthymic, but that rule is not a personal prediction. A clinician interprets duration through the person's history and pattern of episodes.
Can someone have depression while euthymic?
A current full major depressive episode and a strict definition of euthymia are different states. However, mild or residual depressive symptoms can exist below the threshold of a complete episode, and some research samples permit them. Persistent sadness, reduced pleasure, or worsening functioning requires assessment. Marangell et al. shows that subsyndromal symptoms can carry meaningful burden.
Why am I still tired or forgetful when my mood is stable?
Possible contributors include residual depression, poor sleep, a physical condition, medication effects, anxiety, or cognitive difficulties. Group-level studies find cognitive and sleep differences among some euthymic participants, but an individual's symptoms need their own assessment. Swidzinski et al. and Marchetti et al. provide research context.
Should medication be stopped if symptoms are gone?
A symptom-free interval by itself does not establish that maintenance treatment can safely end. Benefits, adverse effects, recurrence history, and personal priorities should be reviewed with the prescriber. Stopping some treatments requires careful tapering and follow-up; abrupt changes may increase risk. NICE's long-term treatment guidance addresses planning and monitoring when medication is discontinued.
Do residual symptoms mean another bipolar episode is approaching?
Residual symptoms can be markers of vulnerability or early change, but they cannot predict an individual's next episode with certainty. The most useful information is whether a symptom is new, sustained, worsening, accompanied by changes in sleep and energy, or similar to previous prodromes. Perlis et al. informs risk interpretation and NICE recommends individualized warning-sign planning.